Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conventional triple negative BC drug long term side effects

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 09, 2024 9:35pm

113 Views

Post# 35818577

RE:Conventional triple negative BC drug long term side effects

In 2021 Pfizer for the first time talked up its own PD-(L)1 challenger, sasanlimab.

Pfizer returned the anti-PD-L1 Bavencio to Merck KGaA in 2023, which it originally licensed in 2014. Interestingly, sasanlimab was also included in that 2014 deal: Pfizer says the molecule had been originated in house, but the two companies agreed to work together on it, before Pfizer regained rights in December 2018, according to US SEC filings.

https://www.evaluate.com/vantage/articles/news/corporate-strategy/pfizer-reveals-its-pd-1-secret

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest